KPV: The C-Terminal Tripeptide of α-MSH as a Research Anti-Inflammatory

Research summary. KPV (lysine-proline-valine) is the C-terminal tripeptide fragment of α-melanocyte-stimulating hormone (α-MSH) and corresponds to ACTH(11–13). Despite its minimal three-residue size, KPV retains a substantial portion of the anti-inflammatory activity of the parent α-MSH while lacking the pigment-inducing activity of the larger peptide. The combination of small size, multiple viable administration routes, and reproducible anti-inflammatory effects in colitis and skin-inflammation models has made KPV a focus of preclinical research, particularly in the context of inflammatory bowel disease.

Molecular profile

• Sequence: Lys-Pro-Val (KPV)
• Molecular formula: C₁₆H₃₀N₄O₄
• Molecular weight: ~342.4 g/mol
• PubChem CID: 125672
• CAS Number: 67727-97-3
• Origin: Endogenous as a fragment of the proopiomelanocortin (POMC)-derived α-MSH peptide

Mechanism of action

KPV's anti-inflammatory activity is mechanistically distinct from that of the intact α-MSH peptide:

• NF-κB pathway suppression — KPV reduces NF-κB nuclear translocation and downstream pro-inflammatory gene expression in epithelial and immune cells.
• MAPK signalling modulation — reductions in p38 MAPK activity have been reported in inflamed intestinal models.
• Cytokine attenuation — particularly TNF-α and IL-8, with corresponding reductions in neutrophil infiltration.
• Activity-dependent uptake via PepT1 — the di/tripeptide transporter PepT1 is upregulated on intestinal epithelium during inflammatory states. KPV is taken up via this route, producing concentrated activity in inflamed (vs healthy) tissue.
• No requirement for melanocortin receptor binding — pharmacological blockade of MC3R/MC4R, the principal receptors for α-MSH-derived anti-inflammatory effects, does not abolish KPV's activity. KPV thus appears to act through an MC-receptor-independent intracellular mechanism, which is consistent with the absence of melanocortin-driven pigmentation.

The activity-dependent (inflammation-gated) uptake via PepT1 is one of the more novel mechanistic features of KPV: the peptide accumulates preferentially where inflammation is present and is largely excreted otherwise.

Preclinical research highlights

Inflammatory bowel disease models. KPV has been studied extensively in DSS- and TNBS-induced rodent colitis models. Reported findings include reduced inflammatory infiltrates, lower MPO activity, attenuated histological inflammation scores, accelerated mucosal recovery, and improved weight-recovery trajectories relative to placebo. Hyaluronic-acid-functionalised nanoparticle delivery formats have been used to concentrate KPV activity at the inflamed mucosa.

Wound-healing and skin biology. Skin cells across multiple wound-healing phases express MC1R and respond to α-MSH-derived peptides. KPV in particular has been studied for retention of anti-inflammatory activity in wound contexts without the pigment-inducing effects of the parent peptide — a notable advantage in cosmetically sensitive applications.

Antimicrobial activity. KPV has been reported to inhibit the growth of Staphylococcus aureus and Candida albicans in cell-culture and ex vivo studies at physiologically achievable concentrations. This combined anti-inflammatory and antimicrobial profile distinguishes KPV from many anti-inflammatory agents that suppress immune defences against infection.

Hypertrophic scar and fibrosis biology. Reduced macrophage infiltration, TNF immunoreactivity, and IL-8/collagen-type-I production have been reported in models exploring KPV in the remodelling phase of wound healing. Reduced MC1R expression in keloid-prone fibroblasts is a long-standing observation in dermatology, and KPV's MC-receptor-independent mechanism may circumvent that limitation.

Multi-route administration. Reported routes of administration in preclinical models include oral, subcutaneous, intravenous, and transdermal. Oral activity is mechanistically supported by intestinal PepT1 uptake.

KPV vs intact α-MSH

α-MSH is generally more potent than KPV as a broad anti-inflammatory but carries pigment-inducing activity through MC1R engagement. KPV retains a substantial portion of the anti-inflammatory profile through an MC-receptor-independent mechanism while losing the pigmentation effect. The trade-off — somewhat reduced potency in exchange for a cleaner side-effect profile and far simpler synthesis — is the principal reason KPV has become the more frequently studied research peptide of the two for inflammatory and wound-healing applications.

Current research status

KPV is an investigational research peptide. It is not approved as a therapeutic by major regulatory authorities. Active research applications include:

• Inflammatory bowel disease pathophysiology and targeted-delivery research
• Topical anti-inflammatory and wound-healing studies
• Antimicrobial peptide research
• Hypertrophic-scar and fibrosis biology
• Reference compound for development of α-MSH-derived analogues with improved pharmacological properties
• Component of multi-peptide research blends (KLOW, KLOWS-8)

Key takeaways for researchers

• KPV is the C-terminal Lys-Pro-Val fragment of α-MSH and a small, accessible research anti-inflammatory.
• Its mechanism is MC-receptor-independent and operates through NF-κB and MAPK suppression and PepT1-mediated activity-dependent uptake.
• It retains anti-inflammatory activity without the pigment-inducing effect of intact α-MSH.
• Strongest preclinical literature is in IBD/colitis models and skin/wound biology.
• KPV is administrable by multiple routes including oral, subcutaneous, and transdermal in preclinical contexts.

References

1. Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008;29(5):581–602.
2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178.

---

This article is provided for educational and research purposes only. KPV is a research peptide. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this peptide should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.